We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+20.22%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$180M
AUM Growth
+$26M
Cap. Flow
+$7.69M
Cap. Flow %
4.26%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$5.32M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.37M

Top Sells

Rank Stock Value
1
VOR icon
Vor Biopharma
VOR
+$80

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INVA icon
1
Innoviva
INVA
$1.61B
$51.4M 28.49%
2,816,022
– –
NBIX icon
2
Neurocrine Biosciences
NBIX
$18.4B
$42.6M 23.59%
303,151
– –
CYTK icon
3
Cytokinetics
CYTK
$10.8B
$32.3M 17.93%
588,357
– –
IRWD icon
4
Ironwood Pharmaceuticals
IRWD
$626M
$20.9M 11.56%
15,919,435
– –
AMRN
5
Amarin Corp
AMRN
$293M
$20.4M 11.28%
1,242,527
– –
LNTH icon
6
Lantheus
LNTH
$6.68B
$9.31M 5.16%
181,450
+85,199
+89% +$5.32M
REGN icon
7
Regeneron Pharmaceuticals
REGN
$72.9B
$2.36M 1.31%
+4,190
New +$2.37M
VOR icon
8
Vor Biopharma
VOR
$1.08B
$1.24M 0.69%
25,399
-2
-0% -$80

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
PWA
Providence Wealth Advisors Frankfort, Illinois $157M AUM 29.27% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SR
Syntax Research Boca Raton, Florida $157M AUM 16.51% 1-Year Est. Return
BRWM
Blue Rock Wealth Management Winston-Salem, North Carolina $157M AUM 18.03% 1-Year Est. Return

Sarissa Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Sarissa Capital Management held 8 positions worth $180M, up 17% from $154M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management deployed $7.69M of net new capital in Q3 2025, opening 1 new position and adding to 1 existing holding. Its largest new stake was Regeneron Pharmaceuticals: 4,190 shares worth $2.36M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Vor Biopharma, an estimated $80 trimmed.

  • Sarissa Capital Management's largest Q3 2025 buy was Regeneron Pharmaceuticals: 4,190 shares worth $2.36M.
  • Sarissa Capital Management added most to Lantheus in Q3 2025, an estimated $5.32M increase.
  • Sarissa Capital Management's biggest Q3 2025 reduction was Vor Biopharma, cutting an estimated $80.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $180M portfolio in Q3 2025.
  • Sarissa Capital Management opened 1 new position and closed 0 in Q3 2025.
  • Sarissa Capital Management's portfolio value rose 17% quarter-over-quarter to $180M.

Based on Sarissa Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.